Proinflammatory and anti-inflammatory cytokines as mediators in the pathogenesis of septic shock

Chest

Volumn 112, Issue 6 SUPPL., 1997, Pages 321S-329S

  Dinarello, Charles A ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; CYTOKINE; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 1BETA CONVERTING ENZYME; INTERLEUKIN 4; INTERLEUKIN 6; METALLOPROTEINASE INHIBITOR; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; NITRIC OXIDE; PLACEBO; PROSTANOID; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR RECEPTOR;

CLINICAL TRIAL; GENE EXPRESSION; HUMAN; INFLAMMATION; MEDIATOR; MORTALITY; PATHOGENESIS; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; REVIEW; SEPSIS; SEPTIC SHOCK;

EID: 0031452476     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.112.6_Supplement.321S     Document Type: Article

References (83)

1. Smith JW, Urba WJ, Curti BD, et al. The toxic and hematologic effects of interleukin-1 alpha administered in a phase I trial to patients with advanced malignancies. J Clin Oncol 1992; 10:1141-52
2. Crown J, Jakubowski A, Kemeny N, et al. A phase I trial of recombinant human interleukin-1β alone and in combination with myelosuppressive doses of 5-fluoruracil in patients with gastrointestinal cancer. Blood 1991; 78:1420-27
3. Chapman PB, Lester TJ, Casper ES, et al. Clinical pharmacology of recombinant human tumor necrosis factor in patients with advanced cancer. J Clin Oncol 1987; 5:1942-51
4. van der Poll T, Bueller HR, ten Cate H, et al. Activation of coagulation after administration of tumor necrosis factor to normal subjects. N Engl J Med 1990; 322:1622-27
5. van der Poll T, van Deventer SJH, Hack CE, et al. Effects of leukocytes following injection of tumor necrosis factor into healthy humans. Blood 1991; 79:693-98
6. Holtmann H, Wallach D. Down regulation of the receptors for tumor necrosis factor by interleukin 1 and 4 beta-phorbol-12-myristate-13-acetate. J Immunol 1987; 139:1161-67
7. Brakebusch C, Varfolomeev EE, Batkin M, et al. Structural requirements for inducible shedding of the p55 tumor necrosis factor receptor. J Biol Chem 1994; 269:32488-96
8. Mathias S, Younes A, Kan C-C, et al. Activation of the sphingomyelin signaling pathway in intact EL4 cells and in a cell-free system by IL-1β. Science 1993; 259:519-22
9. 2 by phosphorylation in rat mesangial cells. J Clin Invest 1994; 93:1224-33
10. 2-activating protein. Proc Natl Acad Sci USA 1991; 88:5418-22
11. Kracht M, Truong O, Totty NF, et al. Interleukin-1α activates two forms of p54α mitogen-activated protein kinase in rabbit liver. J Exp Med 1994; 180:2017-27
12. Guesdon F, Waller RJ, Saklatvala J. Specific activation of β-casein kinase by the inflammatory cytokines interleukin-1 and tumour necrosis factor. Biochem J 1994; 304:761-68
13. Freshney NW, Rawlinson L, Guesdon F, et al. Interleukin-1 activates a novel protein cascade that results in the phosphorylation of hsp27. Cell 1994; 78:1039-49
14. Guesdon F, Freshney N, Waller RJ, et al. Interleukin 1 and tumor necrosis factor stimulate two novel protein kinases that phosphorylate the heat shock protein hsp27 and beta-casein. J Biol Chem 1993; 268:4236-43
15. Moncada S, Palmer RMJ, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991; 43:109-42
16. Kunz D, Mühl H, Walker G, et al. Two distinct signaling pathways trigger the expression of inducible nitric oxide synthase in rat mesangial cells. Proc Natl Acad Sci USA 1994; 91:5387-91
17. Szabo C, Wu C-C, Gross SS, et al. Interleukin-1 contributes to the induction of nitric oxide synthase by endotoxin in vivo. Eur J Pharmacol 1993; 150:157-60
18. Okusawa S, Gelfand JA, Ikejima T, et al. Interleukin 1 induces a shock-like state in rabbits: synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition. J Clin Invest 1988; 81:1162-72
19. Fischer E, Marano MA, Barber AE, et al. A comparison between the effects of interleukin-1α administration and sublethal endotoxemia in primates. Am J Physiol 1991; 261: R442-49
20. Beasley D, Schwartz JH, Brenner BM. Interleukin 1 induces prolonged L-arginine-dependent cyclic guanosine monophosphate and nitrite production in rat vascular smooth muscle cells. J Clin Invest 1991; 87:602-08
21. Tredget EE, Yu YM, Zhong S, et al. Role of interleukin 1 and tumor necrosis factor on energy metabolism in rabbits. Am J Physiol 1988; 255:E760-68
22. Casey LC, Balk RA, Bone RC. Plasma cytokines and endotoxin levels correlate with survival in patients with the sepsis syndrome. Ann Intern Med 1993; 119:771-78
23. Fisher CJJ, Opal SM, Dhainaut J-F, et al. Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis. Crit Care Med 1993; 21:318-27
24. 2 in brain but not in peripheal blood mononuclear cells. Brain Res 1991; 562:199-206
25. Hauptmann B, Van Damme J, Dayer JM. Modulation of IL-1 inflammatory and immunomodulatory properties by IL-6. Eur Cytokine Netw 1991; 2:39-46
26. Kriegler M, Perez C, DeFay K, et al. A novel form of TNF/cachectin is a cell surface cytotoxic transmembrane protein: ramifications for the complex physiology of TNF. Cell 1988; 53:45-53
27. Stevenson FT, Bursten SL, Fanton C, et al. The 31-kDa precursor of interleukin-1α is myristoylated on specific lysines within the 16-kDa N-terminal propiece. Proc Natl Acad Sci USA 1993; 90:7245-49
28. Stevenson FT, Bursten SL, Locksley RM, et al. Myristyl acylation of the tumor necrosis factor-α precursor on specific lysines. J Exp Med 1992; 176:1053-62
29. McGeehan GM, Becherer JD, Bast R Jr, et al. Regulation of tumour necrosis factor-alpha processing by a metalloproteinase inhibitor. Nature 1994; 370:558-61
30. Mohler KM, Sleath PR, Fitzner JN, et al. Protection against a lethal dose of endotoxin by an inhibitor of tumour necrosis factor processing. Nature 1994; 370:218-20
31. Gearing AJH, Beckett P, Christodoulous M, et al. Processing of tumour necrosis factor-α precursor by metalloproteinases. Nature 1994; 370:555-67
32. Lee JC, Laydon JT, McDonnell PC, et al. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 1994; 372:739-47
33. Galcheva-Gargova Z, Dérijard B, Wu I-H, et al. An osmosensing signal transduction pathway in mammalian cells. Science 1994; 265:806-09
34. Han J, Lee J-D, Bibbs L, et al. A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells. Science 1994; 265:808-11
35. Chernoff AE, Granowitz EV, Shapiro L, et al. A randomized, controlled trial of interleukin-10 in humans: inhibition of inflammatory cytokine production and immune responses. J Immunol 1995; 154:5492-99
36. Vannier E, Miller LC, Dinarello CA. Coordinated antiinflammatory effect of IL-4: IL-4 down regulates IL-1 synthesis but up regulates IL-1ra production. Proc Natl Acad Sci USA 1992; 89:4076-80
37. Chantry D, Turner M, Abney E, et al. Modulation of cytokine production by transforming growth factor-beta. J Immunol 1989; 142:4295-4300
38. Dripps DJ, Brandhuber BJ, Thompson RC, et al. Effect of IL-1ra on IL-1 signal transduction. J Biol Chem 1991; 266:10331-36
39. Seckinger P, Lowenthal JW, Williamson K, et al. A urine inhibitor of interleukin-1 activity that blocks ligand binding. J Immunol 1987; 139:1546-49
40. Hannum CH, Wilcox CJ, Arend WP, et al. Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor. Nature 1990; 343:336-40
41. Eisenberg SP, Evans RJ, Arend WP, et al. Primary structure and functional expression from complementary DNA of a human interleukin-1 receptor antagonist. Nature 1990; 343: 341-46
42. Dinarello CA. Biological basis for interleukin-1 in disease. Blood 1996; 87:2095-2147
43. Granowitz EV, Porat R, Mier JW, et al. Hematological and immunomodulatory effects of an interleukin-1 receptor antagonist coinfusion during low-dose endotoxemia in healthy humans. Blood 1993; 82:2985-90
44. Fischer E, van Zee KJ, Marano MA, et al. Interleukin-1 receptor antagonist circulates in experimental inflammation and in human disease. Blood 1992; 79:2196-2200
45. Granowitz EV, Santos A, Poutsiaka DD, et al. Circulating interleukin-1 receptor antagonist levels during experimental endotoxemia in humans. Lancet 1991; 338:1423-24
46. Hyams JS, Fitzgerald JE, Wyzga N, et al. Characterization of circulating interleukin-1 receptor antagonist expression in children with inflammatory bowel disease. Dig Dis Sci 1994; 39:1893-99
47. Mandrup-Poulsen T, Wogensen L, Jensen M, et al. Circulating interleukin-1 receptor antagonist concentrations are increased in adult patients with thermal injury. Crit Care Med 1995; 23:26-33
48. Tilg H, Trehu E, Shapiro L, et al. Induction of circulating soluble tumor necrosis factor receptor and interleukin 1 receptor antagonist following interleukin-1α infusion in humans. Cytokine 1994; 6:215-19
49. Bargetzi MJ, Lantz M, Smith CG, et al. Interleukin-1 beta induces interleukin-1 receptor antagonist and tumor necrosis factor binding proteins. Cancer Res 1993; 53:4010-13
50. van der Poll T, van Deventer SJH, ten Cate H, et al. Tumor necrosis factor is involved in the appearance of interleukin 1 receptor antagonist in endotoxemia. J Infect Dis 1994; 169: 665-67
51. Granowitz EV, Porat R, Mier JW, et al. Pharmacokinetics, safety, and immunomodulatory effects of human recombinant interleukin-1 receptor antagonist in healthy humans. Cytokine 1992; 4:353-60
52. LeMay LG, Otterness IG, Vander AJ, et al. In vivo evidence that the rise in plasma 1L-6 following injection of a fever-inducing dose of LPS is mediated bv IL-1 beta. Cytokine 1990; 2:199-204
53. Dinarello CA, Zhang XX, Wen HD, et al. The effect of interleukin-1 receptor antagonist on IL-1, LPS, Staphylococcus epidermidis and tumor necrosis factor fever. In: Bartfai T, Ottoson D, eds. Neuroimmunology of fever. Oxford: Pergamon Press, 1992; 11-18
54. Fisher CJJ, Slotman GJ, Opal SM, et al. Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled multicenter trial. Crit Care Med 1994; 22:12-21
55. Gershenwald JE, Fong YM, Fahey TJ, et al. Interleukin 1 receptor blockade attenuates the host inflammatory response. Proc Natl Acad Sci USA 1990; 87:4966-70
56. Aiura K, Gelfand JA, Wakabayashi G, et al. Interleukin-1 (IL-1) receptor antagonist prevents Staphylococcus epidermidis-induced hypotension and reduces circulating levels of tumor necrosis factor and IL-1β in rabbits. Infect Immun 1993; 61:3342-50
57. Fisher CJJ, Dhainaut JF, Opal SM, et al. Recombinant human interleukin-1 receptor antagonist in the treatment of patients with sepsis syndrome: results from a randomized, double blind, placebo-controlled trial. JAMA 1994; 271: 1836-43
58. Knaus WA, Harrell FE, Fisher CJ, et al. The clinical evaluation of new drugs for sepsis. JAMA 1993; 270:1233-41
59. Friedman B, Mure A, Brathwaite C, et al. The effects of human recombinant interleukin-1 receptor antagonist (IL-1ra) on plasma levels of prostaglandins and leukotrienes in septic patients [abstract]. Crit Care Med 1994; 22:A193
60. Engelmann H, Novick D, Wallach D. Two tumor necrosis factor-binding proteins purified from human urine: evidence for immunological cross-reactivity with cell surface tumor necrosis factor receptors. J Biol Chem 1990; 265:1531-36
61. Engelmann H, Holtmann H, Brakebusch C, et al. Antibodies to a soluble form of a tumor necrosis factor (TNF) receptor have TNF-like activity. J Biol Chem 1990; 265:14497-504
62. Engelmann H, Aderka D, Rubinstein M, et al. A tumor necrosis factor-binding protein purified to homogeneity from human urine protects cells from tumor necrosis factor toxicity. J Biol Chem 1989; 264:11974-80
63. Olsson I, Gatanaga T, Gullberg U, et al. Tumour necrosis factor (TNF) binding proteins (soluble TNF receptor forms) with possible roles in inflammation and malignancy. Eur Cytokine Netw 1993; 4:169-80
64. Chikanza IC, Roux-Lombard P, Dayer JM, et al. Tumour necrosis factor soluble receptors behave as acute phase reactants following surgery in patients with rheumatoid arthritis, chronic osteomyelitis and osteoarthritis. Clin Exp Immunol 1993; 92:19-22
65. Girardin E, Roux-Lombard P, Grau GE, et al. Imbalance between tumor necrosis factor-α and soluble TNF receptor concentrations in severe meningococcemia: the J5 study group. Immunology 1992; 76:20-23
66. Shapiro L, Clark BD, Orencole SF, et al. Detection of tumor necrosis factor soluble receptor p55 in blood samples from healthy and endotoxemic humans. J Infect Dis 1993; 167: 1344-50
67. van Zee KJ, Kohno T, Fischer E, et al. Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor-α in vitro and in vivo. Proc Natl Acad Sci USA 1992; 89:4845-49
68. Jansen J, van der Poll T, Levi M, et al. Inhibition of the release of soluble tumor necrosis factor receptors in experimental endotoxemia by anti-tumor necrosis factor antibody. J Clin Immunol 1995; 15:45-50
69. Aderka D, Engelmann H, Hornik V, et al. Increased serum levels of soluble receptors for tumor necrosis in cancer patients. Cancer Res 1991; 51:5602-07
70. Aderka D, Engelmann H, Maor Y, et al. Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J Exp Med 1992; 175:323-29
71. Lesslauer W, Tabuchi H, Gentz M, et al. Recombinant soluble TNF receptor proteins inhibit LPS-induced lethality in mice [abstract]. Cytokine 1991; 3:497
72. Lesslauer W, Tabuchi H, Gentz R, et al. Recombinant soluble tumor necrosis factor receptor proteins protect mice from lipopolysaccharide-induced lethality. Eur J Immunol 1991; 21:2883-86
73. Porat R, Paddock HN, Schwaitzberg SD, et al. Glycosylated recombinant human TNF binding protein-1 reduces mortality, shock and production of TNF in rabbit Escherichia coli sepsis. Crit Care Med 1995; 23:1080-89
74. Bertini R, Delgado R, Faggioni R, et al. Urinary TNF-binding protein (TNF soluble receptor) protects mice against the lethal effect of TNF and endotoxic shock. Eur Cytokine Netw 1993; 4:39-42
75. Opal SM. Clinical trials of novel therapeutic agents: why did they fail? In: Vincent JL, ed. Yearbook of intensive care medicine. Berlin: Springer Verlag, 1995; 425-36
76. Beutler B, Milsark PW, Cerami A. Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science 1985; 229:869-71
77. Tracey K, Fong Y, Hesse DG, et al. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteremia. Nature 1987; 330:662-64
78. Mathison JC, Wolfson E, Ulevitch RJ. Participation of tumor necrosis factor in the mediation of Gram-negative bacterial lipopolysaccharide-induced injury in rabbits. J Clin Invest 1988; 81:1925-37
79. Fong Y, Tracey KJ, Moldawer LL, et al. Antibodies to cachectin/tumor necrosis factor reduce interleukin 1β and interleukin 6 appearance during lethal bacteremia. J Exp Med 1989; 170:1627-33
80. Abraham E, Wunderink R, Silverman H, et al. Efficacy and safety of monoclonal antibody to human tumor necrosis factor-α in patients with sepsis syndrome. JAMA 1995; 273:934-41
81. Vincent J-L, Bakker J, Marécaux G, et al. Administration of anti-TNF antibody improves left ventricular function in septic shock patients. Chest 1992; 101:810-15
82. Elliott MJ, Maini RN, Feldmann M, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 1994; 344:1105-10
83. Reinhart K, Wiegand-Löhnert C, Grimminger F, et al. Treatment of severe sepsis with anti-TNF monoclonal antibody MAK 195F: dose-dependent reduction of mortality in patients with elevated IL-6 serum levels [abstract]. Clin Intensive Care 1995; 6:82